Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept. Issue 30 (9th July 2015)

• Record Type: Journal Article
• Authors: Gavillet, Beatris Mastelic; Mondoulet, Lucie; Dhelft, Véronique; Eberhardt, Christiane Sigrid; Auderset, Floriane; Pham, Hong Thai; Petre, Jean; Lambert, Paul-Henri; Benhamou, Pierre-Henri; Siegrist, Claire-Anne
• Is Part Of: Vaccine. Volume 33:Issue 30(2015)
• Page Start: 3450
• Page End: 3455
• Publication Date: 2015-07-09
• Subjects: AlOH aluminum hydroxide -- aP acellular pertussis -- AUC area under the clearance curve -- B. pertussis Bordetella pertussis -- CFU colony-forming units -- DTaP-IPV diphtheria-tetanus-acellular pertussis and poliomyelitis -- EDS epicutaneous delivery system -- EPIT® epicutaneous immunotherapy -- FHA filamentous hemagglutinin -- HRP horseradish peroxidase -- LCs Langerhans cells -- OVA ovalbumin -- PRN pertactin -- PT pertussis toxin -- rPT genetically-detoxified recombinant PT; Vaccine -- Pertussis -- Epicutaneous -- Needle-free -- Adjuvant-free; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.05.089
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: The limited durability of pertussis vaccine-induced protection requires novel approaches to reactivate immunity and limit pertussis resurgence in older children and adults. We propose that periodic boosters could be delivered using a novel epicutaneous delivery system (Viaskin ® ) to deliver optimized pertussis antigens such as genetically-detoxified pertussis toxin (rPT). To best mimic the human situation in which vaccine-induced memory cells persist, whereas antibodies wane, we developed a novel adoptive transfer murine model of pertussis immunity. This allowed demonstrating that a single application of Viaskin ® delivering rPT and/or pertactin and filamentous hemagglutinin effectively reactivates vaccine-induced pertussis immunity and protects against Bordetella pertussis challenge. Recalling pertussis immunity without needles nor adjuvant may considerably facilitate the acceptance and application of periodic boosters.